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Introduction
X-linked adrenoleukodystrophy (X-ALD) is an inherited peroxisomal disorder caused by a defective ABCD1 gene leading to a characteristic accumulation of saturated very long chain fatty acids in blood and tissues. The white matter in the brain, spinal cord, adrenal cortex, Leydig cells and hair follicles is typically affected (Moser, 1997; Kemp et al., 2012; Wiesinger et al., 2015) . With an estimated combined incidence of 1:17 000 in males and females, X-ALD is one of the most common peroxisomal diseases.
Although pronounced phenotypic variation may occur within kindreds, two major forms of X-ALD can be differentiated (Moser, 1997; Kemp et al., 2012; Wiesinger et al., 2015) . First, a chronic neuronopathic form, called adrenomyeloneuropathy (AMN), involving spinal cord and to a lesser extent peripheral nerves in adult males as well as heterozygous females, and characterized by a slowly progressive spastic paraplegia with sensory ataxia. Second, a cerebral demyelinating variant with neuro-inflammation that causes white matter destruction. Cerebral demyelination results in rapid loss of neurocognitive, motor and sensory functions with vegetative state and death within a few years of onset. To date, no triggers or other factors have been identified to predict the onset of this acute inflammatory cerebral form of X-ALD, which affects about a third of all males in childhood (childhood onset cerebral ALD, CCALD). Primary isolated cerebral disease in adolescence or adulthood is uncommon (5-10%), although up to 63% of males with AMN develop secondary cerebral demyelination within 10-15 years (de Beer et al., 2014) . For the purposes of this study, primary and secondary cerebral demyelination with gadolinium enhancement of lesions in adulthood is termed adult cerebral ALD (ACALD). ACALD is as devastating as CCALD: patients rapidly lose cognitive and motor function leading to death.
Allogeneic haematopoietic stem cell transplantation (HSCT) is an established long-term treatment in male children with CCALD (Aubourg et al., 1990; Shapiro et al., 2000; Baumann et al., 2003; Peters et al., 2004; Beam et al., 2007; Miller et al., 2011) , although the mechanism of action is not fully understood Schonberger et al., 2007; Cartier et al., 2014) . Survival and neurological outcome of CCALD patients after HSCT is clearly superior compared to untreated patients Miller et al., 2011) . Despite the significant risks of HSCT, no other effective therapeutic option exists for CCALD. Only a few anecdotal reports of allogeneic HSCT in ACALD are available (Hitomi et al., 2005; Fitzpatrick et al., 2008) . In contrast to male children, the cerebral form in adult males is usually associated with motor and sensory deficits in the lower limbs as well as bladder dysfunction as a consequence of AMN. The pattern of CNS demyelination in adults may also be different (Loes et al., 2003; Eichler et al., 2007) . Moreover, bone marrowderived cells infiltrating the brain may react differently in older patients (Barrett et al., 2015) . The extremely poor prognosis with a median overall survival of 2 years once ACALD enters the phase of active neuroinflammation (van Geel et al., 2001; de Beer et al., 2014) , combined with lack of any other effective treatment, has justified the extension of allogeneic HSCT into the older age group.
We report a retrospective analysis of the feasibility, toxicity and long-term neurological outcomes of 14 adult males treated with allogeneic HSCT for ACALD in four European centres. Based on our combined experience, we propose preliminary guidelines for patient selection and treatment protocols for allogeneic HSCT in this setting.
Patients and methods

Participants
Fourteen adult males underwent HSCT for ACALD in four haematopoietic stem cell transplant centres in Germany, France and UK. Diagnosis of X-ALD was based on elevated concentrations of fasting plasma very long chain fatty acids, and additionally on mutations of the ABCD1 gene (HGNC: 61) in nine patients. Diagnosis of ACALD required the detection of gadolinium enhancement in cerebral demyelinating lesions by brain MRI.
Patient characteristics are summarized in Table 1 . Patients had detailed neurological, neurophysiological, and neuropsychological evaluation as well as MRI exams before and sequentially after HSCT. All patients were offered HSCT on an individually selected compassionate basis in accordance with the practice guidelines of the Working Party on Inborn Errors of the European Group for Blood and Marrow Transplantation (Peters and Steward, 2003) with written informed consent for HSCT. The use of stem cell collections from unrelated donors and cord blood, where appropriate, were approved by the medical advisory boards of the respective national donor search programmes for this indication.
Allograft selection, preparative regimen, and graft-versus-host disease prophylaxis Twelve of 14 patients received allogeneic HSCT from a matched donor after myeloablative conditioning. A matched donor was either a genotypical HLA-identical sibling (n = 3) or a 59/10 HLA-matched unrelated donor (n = 9) confirmed by high-resolution DNA typing of HLA class I (HLA A, B, Cw) and class II (HLA DRB1, DQB1) alleles. Ten of these 12 patients were transplanted with bone marrow, and two patients received granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells based on donor preference. Myeloablative conditioning consisted of busulfan and cyclophosphamide. In two patients it was not possible to identify a suitably HLA-matched donor, and they underwent unrelated cord blood transplantation after reduced-intensity conditioning. All but two patients received additional serotherapy for graft-versus-host disease (GVHD) prophylaxis: polyclonal anti-thymocyte globulin from Genzyme Õ (n = 1), Fresenius Õ (now Neovii Õ ; n = 10), or the monoclonal antibody alemtuzumab (Genzyme Õ ; n = 1). Basic transplant characteristics of all patients are summarized in Table 2 . GVHD prophylaxis and supportive care measures were delivered according to standard of care protocols at the individual centres.
Assessment of engraftment, graftversus-host disease, and toxicity Engraftment with full donor chimerism was defined as 490% donor cells in total nucleated cells at Day + 100 post-HSCT as detected by DNA-based techniques (i.e. short tandem repeats analysis). Diagnosis of acute GVHD was primarily based on clinical criteria; overall staging of acute and chronic GVHD was done according to published criteria. Transplant toxicity was described according to the National Cancer Institute common terminology criteria for adverse events version 3.0 (CTCAE v.3.0) with severe toxicity recorded for adverse events grade 5 3.
Data acquisition and assessment of neurological outcome
Patient-related clinical information was obtained from retrospective review of medical records in each transplant centre and from their neurologists.
Assessment tools were used to analyse changes in disease status: the Adult X-ALD Clinical Symptom score (AACS) (Kö hler and Sokolowski, 1999) to quantify the overall X-ALD neurological impairment, the Kurtzke Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) to assess motor dysfunction, the modified Rankin scale (Rankin, 1957) to describe disability status in daily activities, and the Loes MRI severity score (Loes et al., 1994) to measure the extent of cerebral demyelination. Neurological examination covered the following areas: motor function, sensation, bladder function, as well as overall CNS function including vision, hearing, and speech. AACS, EDSS, and modified Rankin scale were determined for the time points pre-HSCT, worst status during first 6 months post-HSCT, and status $24 months post-HSCT (minimum 512 months) for evaluable patients. In four patients (Patients 1B, 3B, 4S and 7B), no MRI scans were available before the onset of ACALD, while in three patients (Patients 12P, 8B and 9B), post-HSCT MRI could not be obtained due to poor clinical status and early death. In addition to Loes score, MRI scans were reviewed for gadolinium enhancement and patterns of demyelination (parieto-occipital AE long tract pyramidal involvement versus all other patterns). Lesion progression was calculated from sequential MRI scans. Neuropsychometric assessment was performed pre-HSCT and, whenever possible, at various time points post-HSCT. Normalized measures of IQ were generated by appropriate tools according to the centres' preference.
Patients unable to walk without aid or rest for $100 m (EDSS 56), were classified as advanced AMN. Stable motor function post-HSCT was defined as increment in EDSS 51 point with preserved/maintained ambulation (EDSS 57).
Severe deterioration in motor function was classified as increment in EDSS 52 points or to EDSS 57. Stable neurocognition post-HSCT was defined as deterioration in IQ 515 [51 standard deviation (SD)] or no cognitive deterioration as detected by care-givers; severe deterioration in intellectual function was classified as obvious cognitive decline or inability to test for IQ anymore. Moderate deterioration was defined as any deterioration less than severe. For the purpose of this study, events were defined in relation to ACALD progression, i.e. event-free survival was used in this study for surviving patients who retained a stable cognitive function after HSCT.
Statistical analysis
Survival was compared by Kaplan-Meier estimates, and comparisons done by the log-rank method. Categorical variables were compared using the z-test or Fisher's exact test. Comparison of continuous variables was performed by nonparametric tests (Mann-Whitney signed rank test, the KruskalWallis ANOVA with following pair-wise comparisons according to Dunn's method). Before and after analyses were performed for single time points with the Wilcoxon signed rank test or for multiple time points with the Friedman repeated measures ANOVA followed by multiple pair-wise comparisons according to the Tukey's test. Calculations were done using Sigmaplot 11.0 (Systat Inc., San José, CA, USA).
Results
Vital status, engraftment, disease progression-related mortality and transplant-related mortality Table 2 .
Eight of the 14 patients were alive with a median followup of 65 months (range 38-116 months). The estimated overall survival probability was 57.1 AE 13.2% (mean AE SD) (Fig. 1A ). There were no survivors after cord blood transplantation with reduced intensity conditioning (n = 2) nor after myeloablative conditioning and peripheral blood stem cell transplantation (n = 2), while 8 of 10 males after myeloablative conditioning and bone marrow transplantation survived (estimated survival probability 80.0 AE 12.6% (log-rank test 11.48, P 5 0.001) (Fig.  1B) . The small numbers did not permit detection of relevant transplant differences between patients with matched donors.
Full donor chimerism (490% donor cells) was detected in 10 of 11 evaluable patients receiving myeloablative conditioning; one patient showed 80% donor cells (Table 2) . Two males who received cord blood after reduced intensity conditioning did not permanently engraft. In the 12 patients receiving myeloablative conditioning, neutrophil recovery (peripheral neutrophil count 5 500/ml for three consecutive days) occurred at a median of 19.5 days (range: 10-34 days). The incidence of severe GVHD was low: only one patient (8% of all males engrafting with donor cells) developed acute GVHD grade 5 II (grade 4 of the skin), while chronic GVHD was observed in limited form only in four patients.
There was one death from primary disease progression without relevant HSCT complications (Patient 4S). Two further patients died from secondary disease progression after life-threatening infections with transient multi-organ failure (Patient 2H) or graft-rejection (Patient 13P). Three early deaths (21%) were directly transplant-or infectionrelated, either associated with non-engraftment (Patient 12P) or immobility due to advanced AMN (Patients 8B and 9B).
Survival was related to baseline motor dysfunction prior to HSCT: limited AMN (EDSS 5 6) was significantly associated with superior survival compared with advanced AMN [estimated survival probability 77.8 AE 13.9% (n = 9) versus 20.0 AE 17.9% (n = 5); log-rank test 3.91, P = 0.048; Fig. 1C ]. After excluding from the analysis the two patients who failed to engraft, the EDSS gained further prognostic significance with the estimated survival probability increasing to 87.5 AE 11.7% (n = 8) for EDSS 56 versus 25.0 AE 21.7% (n = 4) for EDSS 56 (log-rank test 5.16, P = 0.003).
Neurological status at diagnosis of ACALD and before stem cell transplantation Disease characteristics of the 14 ACALD males before HSCT are summarized in Table 1 .
Cerebral disease was first detected at a median age of 33 years (range: 21-48 years). Ten X-ALD males had been monitored in the years before the onset of ACALD. Four patients were first diagnosed with Addison's disease during adolescence [median age at diagnosis 16.5 years (range: 10-18 years)] in the absence of AMN at that time. Two patients had been diagnosed with AMN at the age of 24 and 31 years because of spastic paraparesis. Three patients were identified by family screening with either no symptoms (Patient 10B; age 15 years), increasing learning difficulties (Patient 14P; age 18 years), or gait disturbances in combination with undiagnosed Addison's disease (Patient 8B; age 23 years). At diagnosis of X-ALD, Patient 14P presented with extensive parieto-occipital leukodystrophy and marked ventricular dilatation but without gadolinium enhancement as indication for arrested CCALD at that time. The median period between diagnosis of X-ALD and onset of ACALD was 132 months (range: 19-266 months) among these 10 patients. In contrast, four patients (Patients 1B, 3B, 4S and 7B) already had evidence of ACALD at their first MRI examination. Although Patient 4S had been originally diagnosed at the age of 24 years by family screening, he was not seen again until 8 years later at which stage he had developed visual and auditory deficits and ataxia. Patient 7B presented with seizures as first symptom. The history of AMN symptoms among these four tended to be shorter than in the other 10 patients (median duration 15.5 months versus 37 months; P = 0.088).
All but one patient (Patient 14P) presented with AMN symptoms, which varied considerably in duration (median 24 months, range 0-266 months) and severity: while three patients had severe motor dysfunction (EDSS 56), two patients displayed no motor dysfunction, and two others showed only a mild limitation in running. There was no correlation between EDSS and age, but some linear correlation between duration of AMN symptoms and EDSS was observed (r = 0.735; P = 0.003). Bladder dysfunction was common and present in 12 patients, with marked impairment in two of them. Sensory dysfunction was overall mild in 13 patients and in Patient 6B was the only AMN symptom.
The median interval from detection of ACALD to HSCT was 9 months (range 3-15 months). During this period there was clinical disease progression in six patients: AMN symptoms in one, cognition in two, and both motor and cognitive functions in three patients. Patient 6B developed a visual field defect, while IQ remained stable. Patient 14P still had a strictly normal neurological exam even before HSCT, while five other patients presented with severe motor disability (EDSS 56). With regard to occupational status, five males had discontinued their established work/profession at onset of ACALD, four of them because of progressive motor dysfunction. In the period prior to HSCT, four more patients were unable to continue working mainly due to neurocognitive decline.
The median IQ before HSCT was 99 (range 72-139). Cognitive deterioration was suspected or reported by relatives in all four patients who showed ACALD in their first brain MRI. Neuropsychological evaluation before HSCT in these patients also suggested deterioration by revealing better verbal IQs than performance IQs (data not shown). In contrast, 7 of 10 patients who were followed up longterm displayed no relevant IQ changes until admission for HSCT (P = 0.018). EDSS at 0-6 = maximum EDSS score during first 6 months post-HSCT. MRI: LS = Loes score; PO = parito-occipital; CC = corpus callosum. TRM = transplant-related mortality.
Neurological outcome early after haematopoietic stem cell transplantation
Significant neurological and/or behavioural changes were observed during the transplant procedure and early follow-up in all but one ACALD patient (Table 3) . Exacerbation of motor disability during the first 6 months post-HSCT was a characteristic feature observed in 12 of 14 patients. The median increment in EDSS was 2.8 points with considerable heterogeneity (range: 0-7 points). Only two patients who did not demonstrate obvious gait disturbances before remained unaffected in their motor function (Patients 6B and 14P). All of the other 12 patients deteriorated further; 10 (71%) of them were at least temporarily unable to walk more than a few meters even with aid (EDSS 57). With the exception of Patient 14P, bladder (and sphincter) dysfunction also became apparent or aggravated during the transplant period, especially with fever caused by serotherapy or infection. Two patients developed seizures during the transplant procedure. Deterioration of neurocognitive function, significant hearing or vision impairment as well as severe disorientation and somnolence occurred in five patients (36%) during early post-transplant phase, four of whom subsequently died. Moderate-to-severe behavioural changes were observed in 11 males (79%), which improved markedly or disappeared in all surviving patients after 6-12 months.
Patients with limited AMN at admission for transplantation (EDSS 56) developed significantly fewer neurological symptoms (other than progressive motor disability) compared to the ones with advanced AMN (1/9 = 11% versus 4/5 = 80%; z = 2.001, P = 0.045).
Long-term neurological outcome after haematopoietic stem cell transplantation
The detailed long-term follow-up for each patient is listed in Table 4 , excluding the three patients who died within the first 6 months post-transplant. Three patients progressively deteriorated during the first year post-HSCT and died from ACALD progression 16 to 36 months after transplant. Eight patients stabilized beyond 6 months post-HSCT and became long-term survivors. Two of these did not deteriorate during the transplant procedure and showed a stable motor function thereafter. Exacerbation of motor disability during the first 6 months post-transplant partly reversed in the other six patients. However, only three males (21% of all transplanted patients) could walk without assistance (EDSS 5 6) 24 months after HSCT. Patient 1B was still unable to walk more than a few meters even with aid (EDSS = 7). The median gain in EDSS in these males was 1.5 points (range 0.5-5 points) compared to baseline status. After 24 months post-HSCT, motor function further improved in four patients, while two deteriorated and two remained stable. Bladder dysfunction improved partly over time, but five of the eight patients showed deterioration in comparison to the pre-HSCT status.
In contrast to motor and bladder function, basic cognitive functions were preserved in all surviving patients. Pure intellectual function remained stable in five patients (36% of all transplanted patients): IQ testing was unchanged in three patients (Patients 3B, 5B and 6B). Patient 11P had unaltered cognitive function, but was classified as 'moderate deterioration' due to significant visual loss. Three other surviving patients (Patients 1B, 7B and 10B) showed a moderate cognitive decline. The deterioration in information processing and learning aptitude in Patient 10B may also have been influenced by prior excessive drug abuse. Among the five patients, who had maintained their vocational status prior to HSCT, two (Patients 6B and 14P) continued as students, one (Patient 11P) was unable to resume work due to severe motor dysfunction and visual loss and two died following HSCT (Patients 2H and 9B).
IQ before HSCT was not predictive for outcome: the five patients with proven or suspected cognitive impairment before transplantation (Patients 1B, 3B, 4S, 7B and 14P) had a variable transplant course and outcome after HSCT.
MRI results
The Loes MRI severity score varied considerably both at onset of ACALD and before HSCT. When ACALD was detected, median Loes score was 4.5 points (range 2-12 points) of maximum 34 points. The four patients with ACALD at first MRI examination (Patients 1B, 3B, 4S and 7B) tended to have a somewhat higher overall Loes score (median 7.8 points, range 4-9 points). Loes score increased during the time period between first detection of ACALD and HSCT to a median 6.5 points (range 2-14 points; P = 0.004). Five patients remained stable, while in six patients (Patients 1B, 4S, 5B, 7B, 8B and 12P) cerebral demyelination progressed by at least 2 points. There was no correlation with progression in Loes score and that of EDSS, AACS, or in Rankin score before HSCT. For the 10 patients with MRI scans performed 6-36 months before the onset of ACALD, the median Loes score progression rate was 1.2 points per year (range 0-5.3 points). For 12 evaluable patients, the median Loes score progression rate between onset of ACALD and HSCT was 2 points per year (0-6 points).
Because of early death or poor condition, three patients did not have MRI follow-up (Table 3) . Only Patient 1B showed minimal contrast enhancement 6 months post-HSCT. None of the 11 patients examined beyond 6 months after transplant showed further gadolinium enhancement of cerebral demyelinating lesions. There was no significant increase in Loes score beyond 12 months post-HSCT in comparison to Loes score before HSCT among the eight survivors [median 8 points (range 2.5-12 points) before HSCT; median 10 points (range 5-12 points) 4 12 months post-HSCT].
The three patients with late death after HSCT tended to show a greater increase in Loes score (median gain 4 points; range 1.5-18 points) compared with the four experiencing moderate deterioration in cognitive function (median gain 1.5 points; range 0-9.5 points) and the four with stable cognitive function (median gain 0.8 points; range 0.5-2 points). New demyelinating lesions after 6.0 (4.4-9.9) 7.0 (4.9-11.4) ns EDSS before HSCT 6.5 (6.4-6.6) 3.5 (2.1-4.0) 50.01 Probability of survival, % 20 AE 18 * 78 AE 14 50.05
All values in bold represent median values (with 25th and 75th percentile). Significance calculated by rank sum test. *Age and probability of survival: Mean AE SD. Significance calculated by student t-test (age) or log-rank test (survival). ns = not significant.
HSCT were detected in only one of the four cognitively stable patients, whereas lesion progression and new lesions were seen in all three patients experiencing late mortality. However, none of these differences were significant. Based on MRI analysis, 10 patients (71%) showed involvement of pyramidal long tract fibres, reflecting AMN (Table 1) . With regard to ACALD, only 7 of 14 patients (50%) were characterized by the typical parieto-occipital pattern without additional involvement of other structures than pyramidal long tract fibres. Among the other seven patients, three patients (21%) demonstrated predominant involvement of the frontal lobe white matter, while four patients (29%) showed demyelinating lesions in other structures (basal ganglia or cerebellum). Although two of the latter (Patients 4S and 5B) displayed additional parieto-occipital involvement, they were classified as an atypical pattern. In contrast to the Loes score itself, the MRI demyelination pattern seemed to have an impact on HSCT outcome: among the 12 males engrafting (cord blood transplantations excluded) the estimated survival of ACALD patients displaying the typical parieto-occipital pattern (with or without projection fibre involvement; n = 6) was 100% versus 33.3 AE 19.2% (n = 6; log-rank test 5.57, P = 0.018) for all other patterns. MRI appearances were further analysed according to the study of Eichler et al. (2007) : Patient 9B had corticospinal tract involvement without corpus callosum involvement, eight patients (Patients 1B, 3B, 4S, 7B, 8B, 10B, 13P and 14P) had corticospinal tract involvement with additional involvement of the splenium or genu, and five patients (Patients 2H, 5B, 6B, 11P and 12P) had no corticospinal tract involvement but other white matter lesions within the brain. Aside from an increased EDSS in the nine patients with corticospinal tract involvement (median EDSS 5.0 versus 2.9), there were no significant differences in age, ratio of progression, rate of lesion progression as well as outcome compared with the other patients. However, the five patients (Patients 1B, 4S, 8B, 9B and 13P) with advanced corticospinal tract axonopathy involving the two internal capsules were older at ACALD onset, had all an EDSS 5 6 before HSCT, and had a significantly poorer post-transplant survival compared with the unaffected patients with a trend for a faster rate of Loes score progression before HSCT among these patients (details summarized in Table 5 ). In this cohort, bilateral involvement of internal capsule identified the same subgroup of patients as the criterion EDSS 5 6 just before HSCT (Fig. 1C) .
Analysis according to baseline status and transplant complications
To analyse neurological status between patients with excellent versus poor survival further, patients were divided into two groups depending on motor disability before HSCT and early transplant complications, i.e. life-threatening to fatal infections during the first 6 months post-transplant and/or graft rejection:
Group I (n = 6) included Patients 3B, 5B, 6B, 7B, 10B and 14P with limited AMN symptoms pre-HSCT (EDSS 5 6) and absence of severe early transplant complications.
Group II (n = 8) included five patients (Patients 1B, 4S, 8B, 9B and 13P) with advanced AMN before HSCT (EDSS 5 6) and three patients (Patients 2H, 11P and 12P) with severe transplant complications.
There was a significant survival advantage for Group I patients with 100% in comparison to Group II patients with 25.0 AE 15.3% (log-rank test 7.06; P = 0.008; Fig.  1D ). Neurological and disability status of both patient groups was quantitatively assessed before as well as early (56 months) and late ($24 months) after HSCT using EDSS, AACS, modified Rankin, and Loes score (Table 6 ). The extent of motor dysfunction was a major criterion to define both groups, consequently the median EDSS at baseline tended to be different between both groups (though not significantly). Patients in both groups deteriorated during the early post-HSCT period in both motor and bladder function as well as cognitive function, reflected by an increase in EDSS (not significant for Group I), AACS, and modified Rankin score. Differences between both groups became apparent during the long-term follow-up: all six patients in Group I survived and partly recovered, i.e. these patients had a 67% and 50% chance fully to preserve cognitive and motor function, respectively (Table 4) , and did not demonstrate significant differences in EDSS, AACS, and modified Rankin score late post-transplant in comparison to baseline status. In contrast, the majority of Group II patients steadily deteriorated and died while the two longterm survivors remained moderately to severely impaired both in their motor and cognitive function (Patient 11P had only visual impairment with preserved cognitive functions). Accordingly, late post-HSCT status was significantly different between Group I and II patients for EDSS and AACS score. There was no significant difference in Loes score, but data were either missing (n = 3) or only available from 8 months post-HSCT (n = 1) for half of the Group II patients.
Of the five patients with an EDSS 5 6 before HSCT, only Patient 1B survived experiencing further cognitive decline (Fig. 2) . A baseline EDSS 5 6 identified a group of nine patients with overall good survival. However, cognitive decline between diagnosis of ACALD and transplantation was associated with further cognitive deterioration post-transplant (Patient 7B). For the remaining eight patients, transplant complications had a major impact on outcome. In the absence of transplant complications, all five patients survived with stable cognitive function, whereas of the three who experienced life-threatening infections and/or graft rejection, only Patient 11P survived with loss of vision.
Discussion
This retrospective study of 14 male patients with ACALD provides proof-of-principle that allogeneic HSCT can arrest inflammatory cerebral demyelination allowing survival with preserved neurocognitive function, at least in a subgroup of patients. The estimated mean survival time of the engrafted 12 patients was 81 months, in contrast to 37-41 months reported for untreated patients with cerebral demyelination (van Geel et al., 2001; de Beer et al., 2014) . Moreover, four patients in our series (29%) maintained completely stable intellectual function, and another four developed only moderately impaired neurocognition over a median follow-up period of more than 5 years. Patients who did not progress 6 to 12 months post-transplant became long-term survivors with preserved cognitive function despite ongoing AMN symptoms. The results of HSCT therefore appear to be similar to that observed in CCALD patients , if transplant is performed in patients with stable cognitive function as well as limited AMN symptoms. The relatively long interval between first detection of ACALD and HSCT of 9 months in comparison to 5.1 months in male children with CCALD (Miller et al., 2011) may offer future improvement.
The small number of patients allows for only cautious comments regarding factors that may improve outcomes.
Similar to established paediatric protocols, most of our adult cohort were treated with a myeloablative busulfanand cyclophosphamide-based regimen. Under these conditions, using bone marrow as a stem cell source appeared to be the best single predictor for survival in this series. However, this conclusion may be biased because of confounding factors related to patients treated with peripheral and cord blood stem cells.
Graft failure occurs more frequently with HLA-mismatched grafts compared to matched donors, in non-malignant versus malignant diseases, and after reduced intensity conditioning compared to myeloablation (Olsson et al., 2013) . According to the same study, graft failure in non-malignant disorders had no effect on survival, whereas graft rejection in our series was associated with death. In CCALD, immunoablation alone without donor engraftment does not prevent progression of disease (Nowaczyk et al., 1997; Miller et al., 2011) . Unrelated cord blood transplantation after myeloablation may be effective in male children with CCALD lacking a matched donor (Beam et al., 2007; Miller et al., 2011) . In these studies, however, the overall survival of patients receiving cord blood cells was inferior to other stem cell sources. Therefore, there should be caution regarding unrelated cord blood for ACALD transplant candidates lacking a matched donor, at least with a reduced-intensity conditioning regimen. A promising future alternative option for patients without a matched donor may be gene-modified autologous haematopoietic stem cell transplantation (Cartier et al., 2009) .
In our series, the two patients who had peripheral blood stem cell transplantation did not survive. Although the reason for failure was most likely due to AMN-related immobility with subsequent life-threatening infections, peripheral blood stem cells may also have a negative impact. Transplantation with peripheral blood stem cell in comparison to bone marrow usually results in faster engraftment, more GVHD (Holtick et al., 2015) and higher mortality in non-malignant diseases (Bacigalupo et al., 2015) . In ACALD patients, prevention of GVHD may be of particular importance. Rapid clinical deterioration after the onset of severe acute GVHD has been observed in CCALD patients (Peters et al., 2004; Miller et al., 2011) and in a patient with ACALD (Fitzpatrick et al., 2008) . In addition, chronic GVHD was associated with temporary deterioration in motor function of an adult patient (Hitomi et al., 2005) . Although overall GVHD incidence in this series was low compared to other transplant patients (Socie et al., 2011) , the only case of significant acute GVHD was observed after peripheral blood stem cell transplantation.
In summary, we therefore recommend the use of a myeloablative, busulfan-based conditioning regimen in combination with bone marrow for transplanting ACALD patients (Box 1). However, we recognize that future research could focus on potential improvements in the conditioning regimen using other agents to reduce the toxicity of the procedure.
In addition to transplant-related factors, the neurological baseline status of ACALD patients also determines the outcome after allogeneic HSCT. In male children with CCALD undergoing HSCT, more deaths resulted from disease progression in advanced patients than from transplant-related problems (Peters et al., 2004) . Although transplant-related mortality in adult patients caused by infection or GVHD may be as high as 30% (La Nasa et al., 2005; Gooley et al., 2010; Peffault de Latour et al., 2012; Bacigalupo et al., 2015) , a survival of 560% in transplanted ACALD patients suggests additional ALD-specific problems. However, an analysis of the impact of neurological status in adults is complicated by the fact that the clinical phenotype of ALD adult males is usually a combination of ACALD itself plus accompanying AMN symptoms.
In ACALD, preserved cognitive function before HSCT was considered to be important for stable long-term outcome. The four patients with progressive cognitive decline between ACALD diagnosis and HSCT, who already displayed cerebral symptoms such as impaired vision and hearing, attention deficits, or seizures before transplant, suggest a disease stage too advanced for satisfactory outcomes from HSCT. This is consistent with a previously-reported Irish adult patient with advanced ACALD (Fitzpatrick et al., 2008) and male children with symptomatic CCALD. The latter display an inferior survival and a greater risk for neurological decline after HSCT than presymptomatic CCALD patients (Peters et al., 2004; Miller et al., 2011) . In contrast, the two patients (Patients 3B and 14P) with suspected deterioration in intellectual function before the diagnosis of ACALD but subsequent 
